Abstract:Background: Cannabinoids bind to cannabinoid receptors type 1 and 2 and produce analgesia in several pain models, but central side effects from cannabinoid 1 receptors limit their clinical use. Because of the pain-relieving effects of cannabinoid 2 (CB2) receptor agonists in inflammation pain, incision pain, and neuropathic pain models, we tested whether spinal CB2 receptor activation would induce antihyperalgesia in cancer pain. Our previous study showed that the 2B subunit of N-methyl-D-aspartate (NR2B) receptor in the spinal cord participates in bone cancer pain in mice. In the present study, we also tested the cannabinoid effect on the expression of NR2B. Methods: Seventy-two mice were randomly allocated to 7 different groups: (1) control; (2) sham and tumor-bearing mice, which include (3) V; (4) J1; (5) J2; (6) J3; and (7) J4. In the groups of tumor-bearing mice, C(3)H/Hej mice were implanted with NCTC2472 fibrosarcoma cells into the femur bone to induce bone cancer-related pain behaviors. The sham mice were implanted with minimal essential medium α modification, whereas the control mice received no injection. On day 14 after implantation, tumor-invoked tactile allodynia and thermal hyperalgesia were assessed. Tumor-bearing mice were assigned to intrathecal administration of the CB2 receptor agonist JWH015 (0.5, 1, and 2 μg), CB2 receptor antagonist AM630 (2 μg), or vehicle, and the assessment of withdrawal thresholds was then performed. Tactile allodynia and thermal hyperalgesia were assessed before administration and at 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours after administration. Spinal NR2B activation of all tumor-bearing mice at 12 hours and 72 hours were determined by reverse transcription-polymerase chain reaction analyses. Results: At day 14 after operation, tumor-evoked tactile allodynia and thermal hyperalgesia were higher in tumor-bearing mice compared with the sham and control mice. Intrathecal administration of JWH015 dose dependently attenuated tumor-evoked tactile allodynia and thermal hyperalgesia but this effect was prevented by intrathecal administration of AM630 30 minutes before. The mRNA expression of NR2B was similar to this result. At 12 hours after administration, the expression of NR2B mRNA in the spinal cord was lower in mice that were administered JWH015 compared with the vehicle group. However, this phenomenon was reversed in the group that was preadministered AM630. Conclusion: These data indicated that intrathecal administration of cannabinoid receptor agonists might relieve cancer pain, probably by reducing NR2B-dependent activity in the spinal cord. These results also suggested that cannabinoids might be a useful alternative or adjunct therapy for relieving cancer pain.

Select terpenes from Cannabis sativa are antinociceptive in mouse models of post-operative pain and fibromyalgia via adenosine A2a receptors

Analgesic Potential of Terpenes Derived from Cannabis sativa

Mesoporous Silica Particles As a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy.

The terpenes camphene and alpha-bisabolol inhibit inflammatory and neuropathic pain via Cav3.2 T-type calcium channels

Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation

Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity

Intrathecal administration of the cannabinoid 2 receptor agonist JWH015 can attenuate cancer pain and decrease mRNA expression of the 2B subunit of N-methyl-D-aspartic acid

Cannabis sativa L. Extract Alleviates Neuropathic Pain and Modulates CB1 and CB2 Receptor Expression in Rat

Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination

The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis

[The effects of various reducing diets in adiposity (author's transl)].

Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests

Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models

Adenosine receptors: Emerging non-opioids targets for pain medications

Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies

Single and Combined Effects of Cannabigerol (CBG) and Cannabidiol (CBD) in Mouse Models of Oxaliplatin-Associated Mechanical Sensitivity, Opioid Antinociception, and Naloxone-Precipitated Opioid Withdrawal

Synthesis And Antiallodynic Activity Of Cannabidiol Analogue On Peripheral Neuropathy In Mice

Peripherally administered cannabinoid receptor 2 (CB2R) agonists lose anti-allodynic effects in TRPV1 knockout mice, while intrathecal administration leads to anti-allodynia and reduced GFAP, CCL2 and TRPV1 expression in the dorsal spinal cord and DRG

A neural circuit for lavender-essential-oil-induced antinociception

In reference to Bosma et al. The course of neurocognitive functioning in high-grade glioma patients.

Polymodal K + channel modulation contributes to dual analgesic and anti-inflammatory actions of traditional botanical medicines